Markets:

Overview

News

Currencies

International

Treasuries

Bausch + Lomb Corporation Common Shares (NY:BLCO)

17.48 +0.36 (+2.10%)

Streaming Delayed Price Updated: 3:18 PM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bausch + Lomb Corporation Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

3 Unpopular Stocks Walking a Fine Line

October 03, 2025

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps...

Via StockStory

Bausch + Lomb Will Release Third-Quarter 2025 Financial Results on Oct. 29 and Hold Investor Day on Nov. 13

September 29, 2025

From Bausch + Lomb Corporation

Via Business Wire

1 Small-Cap Stock to Keep an Eye On and 2 That Underwhelm

September 26, 2025

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...

Via StockStory

Earnings Scheduled For July 30, 2025 ↗

July 30, 2025

Via Benzinga

Examining the Future: Bausch & Lomb's Earnings Outlook ↗

July 29, 2025

Via Benzinga

Bausch + Lomb, Enovis, and Haemonetics Shares Plummet, What You Need To Know

September 25, 2025

A number of stocks fell in the afternoon session after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential...

Via StockStory

Bausch + Lomb Announces Publication of enVista Envy™ Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial

September 11, 2025

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers

September 09, 2025

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb (BLCO) Stock Trades Up, Here Is Why

September 08, 2025

Shares of eyecare company Bausch + Lomb (NYSE:BLCO) jumped 2.9% in the afternoon session after the company announced the U.S. launch of its ASANA gas permeable (GP) lenses. This new product line offers...

Via StockStory

Topics Economy Initial Public Offering Stocks

Bausch + Lomb Launches ASANA™ Gas Permeable Lenses in the United States

September 08, 2025

From Bausch + Lomb Corporation

Via Business Wire

3 Healthcare Stocks Walking a Fine Line

September 05, 2025

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of...

Via StockStory

Topics Stocks

Bausch + Lomb (BLCO) Stock Is Up, What You Need To Know

August 22, 2025

Shares of eyecare company Bausch + Lomb (NYSE:BLCO) jumped 3.1% in the afternoon session after comments from Federal Reserve Chair Jerome Powell raised investor hopes for future interest rate cuts. The...

Via StockStory

Topics Economy Initial Public Offering Stocks

Purple, Bausch + Lomb, Etsy, Intel, and Camping World Shares Are Falling, What You Need To Know

August 21, 2025

A number of stocks fell in the afternoon session after markets continued to decline, as investors grew cautious ahead of a key speech by Federal Reserve Chair Jerome Powell. The move came as U.S....

Via StockStory

Topics Economy Stocks

Medical Devices & Supplies - Specialty Stocks Q2 Highlights: Bausch + Lomb (NYSE:BLCO)

August 20, 2025

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - specialty industry, including Bausch + Lomb...

Via StockStory

Bausch + Lomb Announces Board Changes

August 18, 2025

From Bausch + Lomb Corporation

Via Business Wire

1 Safe-and-Steady Stock with Competitive Advantages and 2 That Underwhelm

August 15, 2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Via StockStory

Bausch + Lomb to Participate in Upcoming Investor Conferences

August 14, 2025

From Bausch + Lomb Corporation

Via Business Wire

Sotera Health Company, Incyte, Exact Sciences, Bausch + Lomb, and Addus HomeCare Shares Skyrocket, What You Need To Know

August 13, 2025

A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer...

Via StockStory

Topics Economy Lawsuit

BLCO Q2 Deep Dive: Product Launches Offset Margin Pressures, Management Highlights Pipeline Investments

August 12, 2025

Eyecare company Bausch + Lomb (NYSE:BLCO) announced better-than-expected revenue in Q2 CY2025, with sales up 5.1% year on year to $1.28 billion. The company’s full-year revenue guidance of $5.1 billion...

Via StockStory

1 Stock Under $50 to Target This Week and 2 We Ignore

August 07, 2025

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some...

Via StockStory

3 Small-Cap Stocks with Warning Signs

August 06, 2025

Via StockStory

Bausch Lomb (BLCO) Q2 Revenue Rises 5% ↗

July 30, 2025

Via The Motley Fool

Why Bausch + Lomb (BLCO) Stock Is Down Today

July 30, 2025

Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 3.1% in the morning session after the company reported mixed second-quarter 2025 financial results where a decline in profitability overshadowed...

Via StockStory

Topics Artificial Intelligence Initial Public Offering

Bausch + Lomb’s (NYSE:BLCO) Q2 Sales Top Estimates, Full-Year Outlook Slightly Exceeds Expectations

July 30, 2025

Eyecare company Bausch + Lomb (NYSE:BLCO) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 5.1% year on year to $1.28 billion. The company’s full-year revenue guidance...

Via StockStory

Bausch + Lomb Announces Second-Quarter 2025 Results

July 30, 2025

From Bausch + Lomb Corporation

Via Business Wire

Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout ↗

July 29, 2025

Bausch Health will acquire DURECT and larsucosterol, aiming for FDA approval of a first treatment for alcoholic hepatitis via Phase 3 trials.

Via Benzinga

Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops

July 29, 2025

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb (BLCO) Q2 Earnings Report Preview: What To Look For

July 28, 2025

Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting earnings this Wednesday before market hours. Here’s what investors should know.

Via StockStory

Topics Artificial Intelligence

Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity

July 22, 2025

EQNX::TICKER_START (OTCQB:AVAI),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(NASDAQ:TEM) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence

Medical Devices & Supplies - Specialty Stocks Q1 In Review: Bausch + Lomb (NYSE:BLCO) Vs Peers

July 20, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Bausch + Lomb (NYSE:BLCO) and its peers.

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.